Hippocratic AI vs ResMed
Side-by-side comparison of AI visibility scores, market position, and capabilities
Safety-focused healthcare AI agents. $3.5B valuation. 115M+ clinical interactions, 99.38% accuracy. Polaris 4.2T-param architecture. $404M raised. Founded 2023, Palo Alto.
About
Hippocratic AI was founded in 2023 with a singular safety-first mission: deploy AI agents in healthcare settings where accuracy is not negotiable and errors carry clinical consequence. The company built its Polaris architecture — a 4.2 trillion parameter ensemble model trained specifically for healthcare interactions — to achieve accuracy rates sufficient for real-world clinical deployment. The name Hippocratic directly invokes the medical ethics principle of "first, do no harm," anchoring the company's product philosophy around safety validation before scale.\n\nHippocratic's AI agents are deployed for patient engagement, care navigation, chronic disease management, and administrative workflows across health systems, payers, and pharmaceutical companies. Its agents conduct voice and text-based interactions with patients — scheduling, medication adherence reminders, post-discharge follow-up, and clinical trial recruitment — at a cost and scale that human staffing cannot match. The platform's 99.38% accuracy rate across 115M+ clinical interactions represents the evidence base the company presents to health system procurement teams evaluating AI for direct patient-facing roles.\n\nHippocratic AI achieved a $3.5B valuation on $404M in total funding, making it one of the most highly valued healthcare AI companies globally just two years after founding. The company's rapid ascent reflects both the severity of the healthcare workforce shortage and the readiness of health system buyers to deploy AI agents for defined, bounded clinical workflows. Hippocratic competes with health AI platforms from Epic, Microsoft, and Google, differentiating through its safety-first architecture, purpose-built healthcare training data, and validated clinical accuracy metrics.
ResMed (RMD) reported ~$4.7B revenue in FY2024. Global leader in cloud-connected devices for sleep apnea, COPD, and out-of-hospital care, with 10M+ connected devices. HQ: San Diego.
About
ResMed Inc. is the global leader in cloud-connected medical devices and software for diagnosing and treating sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions in out-of-hospital settings. Founded in Sydney, Australia in 1989, the company designs and manufactures CPAP (continuous positive airway pressure) machines, masks, ventilators, and related accessories used by patients with obstructive sleep apnea — a condition affecting approximately 1 billion people globally that is chronically under-diagnosed and under-treated.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.